Additionally, since inhibitors of this pathway hold great promise for the treatment of meningiomas harboring SMO mutations, ddPCR mutational analysis in tumor tissue has, once more, implications for targeted-individualized therapy in the SMO-mutated context. This evidence concerns the gene SMO and neoplasm.